Oxurion NV has dosed the first patient in a phase 2 study examining THR-149 in the treatment of diabetic macular edema, according to a press release.
The study, Kalahari, is a randomized, prospective, multicenter investigation looking at the impact of multiple injections of THR-149, a plasma kallikrein inhibitor, in patients whose response to anti-VEGF treatment is suboptimal.
Eighteen patients will be enrolled in the dose-finding part of the study, with results expected in 2021. Approximately 104 patients will then be recruited into the double-masked, active-controlled evaluation of the
Uncategorized